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Abstract
Gelatinase B or matrix metalloproteinase-9 (MMP-9) (EC 3.4.24.35) is increased in inflam-
matory processes and cancer, and is associated with disease progression. In part, this is
due to MMP-9-mediated degradation of extracellular matrix, facilitating influx of leukocytes
into inflamed tissues and invasion or metastasis of cancer cells. MMP-9 is produced as
proMMP-9 and its propeptide is subsequently removed by other proteases to generate pro-
teolytically active MMP-9. The significance of MMP-9 in pathologies triggered the develop-
ment of specific inhibitors of this protease. However, clinical trials with synthetic inhibitors of
MMPs in the fight against cancer were disappointing. Reports on active compounds which
inhibit MMP-9 should be carefully examined in this regard. In a considerable set of recent
publications, two antibiotics (minocycline and azythromycin) and the proteasome inhibitor
bortezomib, used in cancers, were reported to inhibit MMP-9 at different stages of its
expression, activation or activity. The current study was undertaken to compare and to verify
the impact of these compounds on MMP-9. With exception of minocycline at high concentra-
tions (>100 μM), the compounds did not affect processing of proMMP-9 into MMP-9, nor did
they affect direct MMP-9 gelatinolytic activity. In contrast, azithromycin specifically reduced
MMP-9 mRNA and protein levels without affecting NF-κB in endotoxin-challenged mono-
cytic THP-1 cells. Bortezomib, although being highly toxic, had no MMP-9-specific effects
but significantly upregulated cyclooxygenase-2 (COX-2) activity and PGE2 levels. Overall,
our study clarified that azithromycin decreased the levels of MMP-9 by reduction of gene
and protein expression while minocycline inhibits proteolytic activity at high concentrations.
Introduction
Proteolysis of extracellular matrix (ECM) is an important aspect of inflammatory reactions [1].
Whereas ECM remodeling is necessary to enable leukocytes to enter sites of infection to
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eliminate micro-organisms, exaggerated modifications may lead to tissue destruction and
bone and cartilage deformations, such as those observed in rheumatoid arthritis [2]. Therefore,
matrix remodeling is under tight control by protease inhibitors. A known class of matrix
remodeling enzymes are the matrix metalloproteinases (MMPs) which, as their name suggests,
faithfully rely on the presence of a catalytic metal-ion (Zn2+) for their activity [3]. These
enzymes are inhibited by endogenous inhibitors, named tissue inhibitors of metalloproteinases
(TIMPs). Additionally, all MMPs are secreted with a propeptide domain (Fig 1) which inter-
acts with the catalytic zinc-ion and also functions as an inhibitor of enzyme activity, keeping
the pro-enzyme (e.g. proMMP-9) catalytically inactive [4]. Upon the step-wise removal of this
propeptide, for example by MMP-3, MMPs become fully activated and capable of degrading
their substrates [5]. Among MMPs, MMP-9 is unique from several points of view. Structurally,
MMP-9 has an additional domain, called the O-glycosylated domain which offers this MMP
extreme flexibility and allows the protease to ‘crawl’ along large substrates [6]. In addition, we
recently discovered that this flexibility allows the enzyme to bend into doughnut-shaped
homotrimers which differentially interact with TIMP-1 during angiogenesis [7]. From the
physiological perspective, MMP-9 is uniquely placed as it is abundantly secreted by neutro-
phils which, in contrast to other cell types, pre-store MMP-9 in secretory granules, ready for
fast release [8]. As a consequence, MMP-9 is associated with many acute and chronic inflam-
matory diseases: from acute inflammation and shock syndromes to autoimmune diseases and
cancer [9, 10]. Moreover, the role of MMP-9 in inflammation was shown to go beyond leuko-
cyte recruitment and also to affect apoptosis [11] and expression of other enzymes such as
cyclooxygenase [12]. MMP-9 may be inhibited in several ways. The conversion of the inactive
pro-enzyme into its activated form may be blocked, the activated enzymes may be directly
Fig 1. Multi-domain structure of proMMP-9. 3D molecular structure of the full-length human proMMP-9
monomer. The catalytic site is formed by the Zn2+ -binding domain (orange) and the active site (yellow) and is
highly conserved within the MMP family. MMPs are secreted as pro-enzymes, containing a propeptide
domain (green) which interacts with the catalytic Zn2+ ion, thereby keeping the enzyme inactive. The
fibronectin repeats (blue) are only present in gelatinases (MMP-2 and MMP-9) and assist the catalysis of large
substrates such as gelatins. The O-glycosylated domain (black) is a unique domain that, as its name
suggests, is flexible and heavily glycosylated. This domain lends the MMP-9 molecule a high degree of
flexibility and the ability to reach cleavage sites on long substrates. Finally, the hemopexin domain (red) is
present in several MMPs and has a range of functions including substrate binding, inhibitor binding and
binding to cell surface receptors [13, 14].
https://doi.org/10.1371/journal.pone.0174853.g001
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inhibited and the production of proMMP-9 may be blocked at the transcriptional level. Once
formed, the enzyme mRNA may even be silenced [13].
For decades, major investments have been done by the pharmaceutical industry to generate
drugs inhibiting MMPs. Whereas this was primarily with the aim to block tumor cell invasion
and metastasis, more recently, it has been recognized that such pharmaceuticals may have a
future in inflammation research and therapy [15, 16]. From gene knockout studies in mice, it
has been deduced that MMP-9 inhibition may be useful in chronic organ-specific auto-
immune diseases such as multiple sclerosis [17], diabetes [18] and rheumatoid arthritis [19],
whereas the use of MMP-9 inhibitors needs to be questioned for the treatment of systemic
auto-immune diseases [20]. In addition, recent studies indicate that MMP-9 inhibition may
also be beneficial in acute infections and inflammatory syndromes, including endotoxinemia
[21, 22]. However, not many practical MMP inhibitors exist and the ones available are not
therapeutically useful due to a lack of specificity and off-target effects. A persistent lack of
knowledge on the complexity of MMP biology hampers the development of safe and effective
MMP-targeting drugs [15, 16].
For the above reasons, the search for MMP inhibitors continues. One of the possible
approaches to achieve the above goal is to scrutinize active compounds which are already used
clinically for other purposes, for their possible impact on MMPs. During the past years, three
of such compounds were frequently reported to yield downregulated expression of gene or
protein levels of (pro)MMP-9, or alternatively, to inhibit activation of proMMP-9 or activity of
MMP-9. However, in the case of MMPs which are released in inactive form and then become
activated, there is a common misinterpretation of methodological approaches to qualitatively
verify the presence of each form. This especially concerns gelatin gel zymography which is a
technique that is commonly used to detect gelatinases (in particular MMP-2 and MMP-9) in
complex biological samples (e.g. plasma and tissue extracts). This technique exploits the fact
that MMPs, after electrophoretical separation (SDS-PAGE), can be refolded into active
enzymes, including proMMPs and MMPs that were previously attached to inhibitors. There-
fore, this technique gives information on the potential gelatinolytic activity present in each
sample but yields no information about the net proteolytic activity, a commonly made error in
interpretation [23].
Many publications on MMP-9 inhibitors report that minocycline, azithromycin and borte-
zomib possess one or several of the above capacities (S1 Table). For example, human mono-
cytes and PBMCs treated with azithromycin produced less MMP-9 protein [24] as did airways
of lung transplant patients treated with azithromycin [25]. Azithromycin is commonly used as
an antibiotic in the treatment of respiratory, urogenital and dermal infections. Besides antibi-
otic properties it also has immunomodulatory properties, and is therefore also being used for
the treatment of chronic inflammations such as panbronchiolitis, post-transplant bronchiolitis
and rosacea. However, a clear-cut mechanism of this anti-inflammatory effect is still not
known [26]. Minocycline is a broad-spectrum tetracycline antibiotic, mainly used for treat-
ment of acne vulgaris and sexually transmitted diseases. While its anti-microbial activities are
based on inhibition of the bacterial 30S ribosomal subunit and inhibition of protein synthesis,
it is believed that the non-microbial activities are due to the inhibition of several enzymes,
including MMPs [27–29]. Minocycline and azithromycin are used in similar diseases e.g. dur-
ing infection with Chlamydia spp. [30] and are more effective when used together [31]. In con-
trast, bortezomib is a proteasome inhibitor and thus inhibits intracellular degradation of
proteins, leading to cell apoptosis [32]. Since MMP-9 also possesses anti-apoptotic effects
through its hemopexin domain [11, 33], bortezomib might also target MMP-9. In the clinic,
bortezomib is used as a treatment of multiple myeloma (MM) [34].
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Based on the reports on effects of minocycline, azythromycin and bortezomib on MMP-9
we undertook biochemical and immunological studies to complement existing studies and to
compare the possible inhibitory mechanisms against MMP-9 and at which stage of its expres-
sion or activation these act. Against prevailing notion, we showed that decreased levels of
MMP-9, observed in macrophage-like THP-1 cells incubated with bortezomib, resulted
entirely from its cytotoxic effect and this drug did not affect the activity of the protease. Con-
versely, minocycline and azithromycin did not reduce cell viability but mainly prevented
MMP-9 expression at the gene and/or protein levels. However, these two antibiotics did not
have an effect on activation of proMMP-9 and only high doses of minocycline (50–100 μM)
affected gelatinolytic activity.
Materials and methods
Reagents
Bortezomib (sc-217786), azithromycin (sc-254949), minocycline (sc-203339) and SB-3CT (sc-
205847) were purchased from Santa Cruz Biotechnology (TX, USA). LPS from Escherichia coli
0111:B4 (L4391) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant
human full-length proMMP-9 (92 kDa) was expressed in Sf9 insect cells and purified by
gelatin-Sepharose chromatography. ProMMP-9 was activated by incubation with the catalytic
domain of stromelysin-1/MMP-3 (cat. No. 444217, Merck Millipore, Darmstadt, Germany).
The recombinant expression, purification and activation of proMMP-9 were performed as
described previously [14, 35].
Gelatin zymography
Samples in non-reducing loading buffer were loaded on standard 7.5% polyacrylamide gels
containing 0.1% gelatin. After electrophoresis the gels were washed twice for 20 minutes with
2.5% Triton X-100 to remove SDS. Next the gels were incubated overnight at 37˚C in incuba-
tion buffer (50 mM Tris, 10 mM CaCl2, 0.02% NaN3, 1% Triton X-100, pH 7.5) for gelatin deg-
radation. For activity inhibition experiments, the gel was sliced into separate lanes and each
lane was treated separately from this point on. Specifically, for these experiments, all lanes in
the gels were loaded with equivalent quantities of human recombinant MMP-9 and after elec-
trophoresis these gels were sliced into strips. Next, different concentrations of compounds
were added to the incubation buffer and each strip of gel was incubated with a different com-
pound/concentration. Finally, the gels were stained with the PhastGel Blue R-350 staining kit
(GE Healthcare, Piscataway, NJ, USA) and the densities of the bands were analyzed with the
ImageQuant TL software (GE Healthcare, Piscataway, NJ, USA)[23].
Gelatin degradation assay
A gelatin degradation assay [36] was used to study the inhibitory effect of bortezomib, azithro-
mycin, minocycline and SB-3CT on the degradation of gelatin by MMP-9. Briefly, 10 nM of
active MMP-9 was incubated with 60 μM, 40 μM and 20 μM of the test compound and incu-
bated for 30 min at 37˚C. Next, a fluorogenic gelatin substrate (DQ-gelatin™, Invitrogen, Carls-
bad, CA, USA) was added to this mixture and the increase in fluorescence was recorded every
10 min for 2 hours. Percentages of inhibition were calculated by comparing the initial velocity
of each condition with a condition without compound.
Cell culture, viability and experimental design
THP-1 cells (106 cells in 1 ml RPMI medium, without antibiotics, growth factors or serum)
were seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 μl of the
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test compound was added followed by 50 μl of LPS (final concentration of 10 μg/ml). After
24h (37˚C and 5% CO2) the supernatants and cell pellets were collected (1200 rpm, 5 min).
THP-1 cell viability was tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT). MTT was purchased (cat. No. M5655, Sigma-Aldrich, St. Louis, MO, USA)
and dissolved at 2 mg/ml in PBS and aliquots were stored at -20˚C. The MTT assay was per-
formed according to the suppliers instructions. Absorbance of MTT converted into formazan
was measured at a wavelength of 570 nm with background subtraction at 630 nm. The
obtained data was presented as percentage of the LPS condition. For cell culture medium sam-
ples, the total protein content was determined and used to normalize sample preparation
before gelatin zymography. HUVEC cell culture and experimental procedures can be found as
supplementary protocol 1 (S1 Protocol)
RNA extraction and qPCR
Total RNA was extracted using the RNeasy Mini Kit (74106, Qiagen, Hilden, Germany). Next,
the quality and concentration of the extracted RNA was determined with the use of a Nano-
Drop Spectrophotometer and, subsequently, complementary DNA was generated using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time qPCR was
performed by using PrimeTime1 Predesigned qPCR Assays, purchased from Integrated DNA
Technologies (IDT, Coralville, IA, USA). The following gene expression assays were used:
MMP2, Hs.PT.58.39034246; MMP9, Hs.PT.58.22814824.g; TIMP1, Hs.PT.58.27632928;
NFKBIA, Hs.PT.58.2372284.g; PTGS2, Hs.PT.58.77266. Expression levels were normalized to
the expression housekeeping gene GADPH Hs.PT.39a.22214836.
ELISA & Western blot
ELISAs were performed on cell culture supernatant of treated THP-1 cells. Levels of IL-1β were
determined using a commercially available Human IL-1 beta DuoSet ELISA (cat. No. DY201-
05, R&D Systems, Minneapolis, MN, USA). Prostaglandin E2 (PGE2) levels were determined
by using a PGE2 express ELISA kit (cat. No. 500141, Cayman Chemical Company, Ann Arbor,
MI, USA). For Western blot analysis, intracellular proteins from 2x106 treated THP-1 cells were
extracted in RIPA buffer (N653, AMRESCO VWR life sciences, Radnor, PA, USA) supple-
mented with protease inhibitors (Complete mini, EDTA-free tablets, Roche, Basel, Switzerland)
and phosphatase inhibitors (phosphatase inhibitor cocktail 2&3, Sigma-Aldrich, St. Louis, MO,
USA) using the protocols provided by the suppliers. The total protein concentration of each
extract was determined using a BCA protein assay kit (cat. No. 23225, Pierce—Thermo Scien-
tific, Waltham, MA, USA). Next, 20 μg of each cell extract was separated on a mini-gel system
(Amersham ECL Gel Box), using a 4–12% precast Amersham ECL Gel (GE Healthcare, Piscat-
away, NJ, USA) and Tris-glycine electrophoresis buffer, under reducing conditions. Thereafter,
proteins were blotted onto a PVDF membrane using a Trans-Blot Turbo transfer system (Bio-
rad, Hercules, CA, USA). The following primary antibodies were used: anti-Phospho-NF-κB
p65 (Ser536) (Rabbit mAb #3033, Cell Signaling Technology, Danvers, MA, USA), anti-actin
(rabbit pAb, 20536-1-AP, protein tech, Rosemont, IL, USA), anti-caspase-4 (rabbit pAb, C4481,
Sigma-Aldrich, St. Louis, MO, USA) at dilutions of, respectively, 1/1000, 1/2000 and 1/250.
Results
Effects on MMP-9 proteolytic activity—Gelatin degradation
In order to evaluate effects of the tested compounds on MMP-9 we took the downstream
approach i.e. first we investigated whether minocycline, azithromycin or bortezomib could
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inhibit MMP-9 gelatinolytic activity. To test high concentrations, compounds were added
in vitro to the developing buffer of a gelatin zymography gel and SB-3CT, a molecule known to
inhibit MMP-9 activity, was used as a control (Fig 2A). While SB-3CT inhibited MMP-9 at
concentrations lower than 5 μM, bortezomib and azithromycin had no effect on the develop-
ment of MMP-9 activity. As expected from previous research [27], minocycline inhibited
MMP-9 when present at high concentrations (>50 μM). Next, we confirmed these results by
using a second technique: a microtiter-based gelatin degradation assay [36] (Fig 2B). With this
test, we were able to compare the inhibitory profile of all four compounds in one plate. While
bortezomib and azithromycin did not inhibit gelatinolysis, the IC50 of SB-3CT and minocy-
cline were respectively 1.75 μM and 272 μM, which is in agreement with previous research
[27]. While SB-3CT showed a strong inhibitory profile, no effect was observed from azithro-
mycin or bortezomib.
Effects on MMP-9 activation by MMP-3
MMP-9 is secreted as an inactive pro-enzyme (proMMP-9) which becomes fully active upon
removal of the inhibitory pro-domain by other proteinases. So far, the best studied activator
of proMMP-9 is MMP-3 which activates proMMP-9 in two steps, each step resulting in a
decrease in molecular weight of approximately 5 kDa [37]. Therefore, we tested whether
activation by MMP-3 is influenced by the compounds. After two hours of incubating
proMMP-9 with MMP-3, no difference in residual MMP-9 gelatinolytic activity was found for
minocycline, azithromycin and bortezomib. As expected, SB-3CT generally reduced gelatin
degradation (Fig 3A). To study the stepwise activation of proMMP-9 in detail, samples were
taken at different times of the activation process, and analyzed by gelatin zymography. A step-
wise activation of proMMP-9 (blue, 92kDa) into an intermediate form (orange, 86 kDa) and
the fully activated MMP-9 (red, 82 kDa) was also seen in the presence of minocycline, azithro-
mycin and bortezomib (Fig 3B and 3C). Compound SB-3CT delayed the first cleavage into the
intermediate proMMP-9 form. Inhibition of MMP-3 activity by SB-3CT at higher concentra-
tions has been reported before and clarifies the delayed activation which we observed here
[38].
Effects on protein expression of (pro)MMP-9
The effects of the drugs were subsequently evaluated at the cellular level. MMP-9 is predomi-
nantly produced by myeloid cells (e.g. neutrophils, monocytes and macrophages), while the
secretion of MMP-9 by other cell types (e.g. fibroblasts, endothelial cells,..) is minimal (S2
Fig). In addition, while neutrophils have MMP-9 pre-stored in secretory granules, mononu-
clear leukocytes de novo synthesize MMP-9 upon stimulation [8]. For these reasons, human
myelomonocytic (THP-1) cells are often used to study cellular effects of drugs on MMP-9
secretion. THP-1 cells were incubated with different concentrations of each compound and
were then challenged with E. coli lipopolysaccharide (LPS), mimicking an inflammatory con-
dition [39]. Next, we evaluated the presence of gelatinases by gelatin zymography (Fig 4A). At
high concentrations (20 μM), minocycline and azithromycin were able to reduce the amounts
of secreted proMMP-9 protein (Fig 4B), while proMMP-2 protein levels remained unaltered
(Fig 4C). In contrast, treatment with bortezomib significantly reduced both MMP-2 and
MMP-9 levels at concentrations as low as 200 nM. Next, we evaluated the effects of the com-
pounds on cell viability. LPS stimulation did not significantly affect cell viability in the
absence of tested compounds (Fig 5A). In contrast, bortezomib treatment resulted in clear
cell toxicity at concentrations down to 200 nM in both THP-1 (Fig 5B) cells and HUVEC
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Fig 2. The effect of minocycline, azithromycin, bortezomib and SB-3CT on MMP-9-mediated
gelatinolysis. (A) gelatin zymography of MMP-9 mixtures (MMP-9 trimers and MMP-9 monomers). Each gel
slice was incubated with a different concentration of each compound, as indicated on top of the lanes.
Representative image of two independent experiments. (B) Percentage of inhibition of MMP-9 mediated
gelatinolysis, as measured using a gelatin degradation assay. Compound concentration ranged from 1000 μM
to 0.24 μM. Data combined from seven independent experiments, including different concentration ranges
and a dose-response curve was fitted using non-linear regression. Higher concentrations of bortezomib and
azithromycin were not tested in the gelatin degradation assay, due to solvent interference. Individual data
points are shown. Statistical analysis was performed for the data at 125 μM by using a Bonferroni’s multiple
comparison test. **, p 0.01; **** p 0.0001.
https://doi.org/10.1371/journal.pone.0174853.g002
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cells (S1 Fig). Interestingly, the MMP-9 inhibitor SB-3CT (20 μM), minocycline (2 μM) and
the antibiotic azithromycin (6 μM) were not cytotoxic but instead stimulated THP-1 cell
growth. Low concentrations of bortezomib (20 nM) also stimulated THP-1 cell growth
(Fig 5B).
Fig 3. Inhibition of proMMP-9 activation by MMP-3. (A) The influence of minocycline, azithromycin,
bortezomib and SB-3CT on the activation of proMMP-9 into MMP-9, measured by assessing the gelatinolytic
activity of proMMP-9 after incubation with a proMMP-9 activator (catalytic domain of MMP-3) in the presence
of the compounds. Data were compared to a condition without compound and expressed as percentage of
activated proMMP-9. Individual data points, each representing a separate experiment, are shown. The bars
represent the mean value. Inhibition of proMMP-9 activation by SB-3CT was significantly different as
determined with a Bonferroni’s multiple comparisons test. ***, P 0.001. (B) Zymography analysis of
proMMP-9 activation by cdMMP-3 in the presence of minocycline, azithromycin, bortezomib and SB-3CT.
Zymograms, representative for three experiments, show the stepwise activation of proMMP-9, from the full-
length enzyme (proMMP-9, blue), to the partially activated enzyme (proMMP-9’, orange) and the fully
activated enzyme (MMP-9, red) as indicated by the arrows. (C) Densitometric analysis of the zymograms. The
proportions of pro, intermediate and activated MMP-9 are shown as the percentages of the total MMP-9.
Individual data points, each representing a separate experiment, are shown.
https://doi.org/10.1371/journal.pone.0174853.g003
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Fig 4. Zymography of THP-1 cells challenged with LPS and treated with minocycline, azithromycin,
bortezomib and SB-3CT. (A) Overview image of the zymography analysis showing a compilation of
representative zymography gels. Prior to zymography, loading volumes were corrected for the total protein
content of each sample. Equal amounts of an internal loading control (±48 kDa MMP-9 mutant lacking the
O-glycosylated and hemopexin domain [14]) were included to allow correction for sample processing and
loading errors. hrMMP-9, human recombinant proMMP-9. (B) Densitometry analysis of proMMP-9 bands.
(C) Densitometry analysis proMMP-2 bands. Individual data points are shown and the bars represent the
mean value. Data were statistically analyzed using a Bonferroni’s multiple comparison test. *, p 0.05;
**, p 0.01; *** p 0.001; **** p 0.0001; n = 2–3.
https://doi.org/10.1371/journal.pone.0174853.g004
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Fig 5. The effect of minocycline, azithromycin, bortezomib and SB-3CT on cell viability of LPS-
stimulated THP-1 cells. (A) The effect of LPS on cell viability evaluated by measuring cell metabolic activity
(MTT assay). Stimulation of THP-1 cells with LPS had no significant effect on the cell viability as determined
with a Mann—Whitney U test. Data represented as background-subtracted absorbance (570 nm– 630nm).
Individual data points are shown and the bars represent the mean value. Ns, not significant; n = 5. (B) The
effect of LPS stimulation of THP-1 cells in combination with minocycline, azithromycin, bortezomib and SB-
3CT on cell viability. The cell viability is expressed as the percentage of cells compared to the condition (LPS
only, no compounds). Individual data points are shown and the bars represent the mean value. Mann—
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Effects on MMP-9 gene expression
Next, we evaluated gene expression of MMP-2 and MMP-9. To avoid effects derived from cell
viability, all samples were corrected for total RNA and for the housekeeping gene GADPH. At
the mRNA level, bortezomib and azithromycin significantly reduced steady-state MMP-9
mRNA levels while minocycline showed a minor but non-significant reduction at 20 μM.
Comparable to the protein level, MMP-2 mRNA levels were significantly reduced by bortezo-
mib. (Fig 6). Additionally, we evaluated expression of other genes to verify specificity towards
MMP-9. The selected genes were TIMP1 and NFKBIA as the former encodes the endogenous
MMP-9 inhibitor TIMP-1 and the latter, NFκB, acts downstream of LPS signaling through
Toll-like receptor-4 activation and is a master switch that controls transcription of the majority
of pro-inflammatory genes, including MMP-9. In contrast to MMP-9, the expression of
TIMP1 and NFKBIA was unchanged by minocycline and azithromycin, strongly suggesting
that the effects of azithromycin were MMP-9 specific (Fig 6). In contrast, bortezomib persisted
to reduce gene expression by also reducing TIMP1 and NFKBIA mRNA, in line the above
mentioned toxicity profile.
Cell signaling events leading to reduced MMP-9 expression
Finally, we investigated which signaling events and pathways drive the specific MMP-9 reduc-
tion caused by minocycline and azithromycin. Since MMP-9 is seen as a pro-inflammatory
molecule, simultaneously secreted with other molecules (e.g. cytokines) we first evaluated
whether NF-κB phosphorylation might be affected. At a concentration of 6 μM neither mino-
cycline nor azithromycin affected NF- κB phosphorylation in comparison to cells only stimu-
lated with LPS (Fig 7A). Among cytokines which can induce MMP-9 expression [39], IL-1β
was previously reported to be reduced by azithromycin, independently of NF- κB [40]. There-
fore, we next evaluated the presence of IL-1 β in cell supernatants. Indeed, at a concentration
of 20 μM a reduction of IL-1β could be found both for azithromycin, but also for minocycline
(Fig 7B). In line with all previous results bortezomib in excess of 200 nM resulted in shut-off of
IL-1β production, probably by toxicity effects. Interestingly, treatment with SB-3CT resulted
in a drastic increase of IL-1β. Previously, the effect of azithromycin on IL-1β was attributed to
a reduction of caspase-4, reduced inflammasome activation and IL-1β maturation. Therefore,
we also evaluated the intracellular presence of caspase-4 (Fig 7A). Caspase-4 was not altered by
minocycline, azithromycin or SB-3CT, while bortezomib again showed a significant decrease.
Prostaglandins are mediators of inflammation and apoptotic pathways, which are produced
from arachidonic acid by the cyclooxygenase (COX) enzymes [41]. In addition, we have previ-
ously shown that MMP-9 deficiency results in augmented PGE-2 secretion [12]. Therefore, we
investigated whether the compounds could affect cyclooxygenase-2 (COX2) and its product,
prostaglandin E2 (PGE2). In contrast, minocycline and azithromycin did not affect COX2
(Fig 7C). Moreover, these results were complemented with according alterations in secreted
prostaglandin E2 levels (Fig 7D).
Discussion
We compared the effects of minocycline, azithromycin and bortezomib on MMP-9 activity,
activation and mRNA/protein expression as numerous publications reported that the
Whitney U tests were used to compare with the control condition (LPS condition) *, p 0.05; **, p 0.01;
*** p 0.001; **** p 0.0001; n = 3–5.
https://doi.org/10.1371/journal.pone.0174853.g005
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compounds can affect these processes (for an overview, see S1 Table). In addition, several
of these studies yielded different outcomes, did not discriminate between pro or activated
forms of MMP-9, did not study activation versus activity and lacked information about specific
comparisons. Our study revealed that in fact none of these compounds affected activation
of the MMP-9 pro-enzyme (for an overview of the results, see Table 1). At high concentrations,
minocycline, but not the other two compounds, inhibited MMP-9 proteolytic activity. Previ-
ous reports documented an IC50 value of 180 μM for minocycline [27, 42]. Our data indeed
show that minocycline inhibits MMP-9 gelatinolytic activity in the micromolar range
(IC50 = 272 μM) when tested in our gelatin degradation assay. Peak minocycline concentra-
tions in patients treated with a dose of 200 mg minocycline range between 6 and 19 μM [43].
In this range no inhibition of MMP-9-mediated gelatinolysis was observed which implies that
Fig 6. qPCR analysis of LPS-challenged THP-1 cells, treated with minocycline, azithromycin, bortezomib and SB-3CT. Fold changes of
MMP2, MMP9, TIMP1 & NFKBIA mRNA levels are shown, relative to the levels from cells treated with LPS only and corrected towards the
housekeeping gene GADPH. Individual data points are shown and the bars represent the mean values. Data were statistically analyzed with the use
of a Bonferroni’s multiple comparison test. *, p 0.05; **, p 0.01; *** p 0.001; n = 3.
https://doi.org/10.1371/journal.pone.0174853.g006
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the effect of minocycline on MMP-9 activity felt outside the window for therapeutic treatment.
Importantly, we found that azithromycin suppresses MMP-9 mRNA and protein expression
by LPS-stimulated human myelomonocytic cells. Pharmacokinetic analysis of azithromycin
(500 mg/day) in cystic fibrosis patients revealed sputum concentrations of ±40 μM while blood
and serum concentrations were around 1 μM [44]. Therefore, the levels of azithromycin to
Fig 7. Cell signaling events leading to reduced MMP-9 expression. (A) Western blot analysis of intracellular, phosphorylated NF-κB
(Ser536) and caspase-4 in THP-1 cells stimulated with LPS and treated with 6 μM minocycline, 6 μM azithromycin, 2 μM bortezomib or no
treatment (cells + LPS without any of the compounds). Western blot images show two samples per condition. Graphs are based on densitometry
analysis of Western blot images (n = 3). (B) IL-1β quantification by ELISA. THP-1 cells were challenged with LPS and 20, 6 and 2 μM of
minocycline or azithromycin. Bortezomib was used at concentrations of 20 μM, 2 μM, 200 nM and 20 nM. (C) qPCR analysis of THP-1 cells
challenged with LPS after treatment with minocycline, azithromycin, bortezomib and SB-3CT. Fold changes COX2 mRNA levels are shown,
relative to cells treated with LPS only and corrected towards the housekeeping gene GADPH. (D) PGE2 ELISA on cell supernatants of THP-1
cells stimulated with LPS and treated with the compounds. Individual data points are shown and the bars represent the mean value. Horizontal
dotted line always indicates cells only treated with LPS. Data were statistically analyzed using a Bonferroni’s multiple comparison test.
*, p 0.05; **, p 0.01; *** p 0.001; n = 3.
https://doi.org/10.1371/journal.pone.0174853.g007
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inhibit MMP-9 expression can be reached in the airways of cystic fibrosis patients treated with
azithromycin. Importantly, the effect on MMP-9 gene expression was specific for this MMP as
expression of MMP-2 (another gelatinase), TIMP-1 (endogenous MMP-9 inhibitor) and
COX-2 (inflammation-activated gene encoding eicosanoids) were not affected by azithromy-
cin and minocycline at these concentrations. Minocycline and azithromycin might therefore
be helpful in diseases where MMP-2 and MMP-9 have opposing effects. An example of such a
disease is arthritis, where MMP-2 is a disease suppressor whereas MMP-9 contributes to
pathology [45].
Expression of MMP-9 can be induced by multiple factors such as cytokines, including IL-
1β [46]. For this reason we verified if its levels correlated with the effect of the compounds on
MMP-9 expression. Indeed, while LPS alone induced IL-1β, this induction was decreased
when cells were subsequently treated with minocycline or azithromycin. De novo expression of
both IL-1β and MMP-9 is regulated by the transcription factor NFκB. However, we showed
that (at a 6 μM concentration) the reduction in MMP-9 levels upon treatment with minocy-
cline and azithromycin was independent of NFκB. Specifically, NF-κB-independent reduction
of LPS-induced IL-1β secretion was previously described for azithromycin [40] Moreover,
treatment of human monocytes with azithromycin had an impaired induction of caspase-4
which was recently described as a new intracellular LPS sensor [47, 48]. Indeed, pharmacoki-
netics of macrolide antibiotics such as azithromycin show a predominant accumulation in
white blood cells [49]. In summary, while we could show an NF-κB-independent effect on IL-
1β for azithromycin and minocycline, the effects on caspase-4 were not corroborated in our
experiments. However, it is still possible that this caspase-4 dependent effect occurs at higher
dosages (> 20 μM).
Whereas the antibiotics minocycline and azithromycin may act directly through effects on
MMP-9, effects for bortezomib may be non-specific and predominantly derived from cells
under severe stress due to the high toxicity of bortezomib. Peak plasma bortezomib concentra-
tions in patients following a standard drug scheme (1.3 mg/m2 on days 1,4,8 and 11 of 21-day
cycles) ranged between 0.5 μM and 0.05 μM [50]. This is indeed within our tested concentra-
tion range showing high toxicity on THP-1 cells. In addition, we here confirm the double-
edged effect of bortezomib, impairing cells at a high concentration (from 100–200 nM) and
inducing cell proliferation at a lower concentration (from 10–20 nM), as was previously
shown [51]. While our data are in line with the previous report that bortezomib prevents deg-
radation of IκB, and in turn blocks NF-κB activation and suppresses cytokine and survival
Table 1. Summarizing table of the results.
minocycline azithromycin bortezomib SB-3CT
MMP-9 activity weak inhibitor no effect no effect strong inhibitor
MMP-9 activation no effect no effect no effect weak effect by inhibiting MMP-3
MMP-9 mRNA trend towards reduction reduction reduction increase
proMMP-9 protein reduction reduction reduction no effect
MMP-2 mRNA no effect no effect reduction reduction
proMMP-2 protein no effect no effect reduction no effect
IL-1β protein reduction reduction reduction increase
TIMP-1 mRNA no effect no effect reduction no effect
Nfkbia mRNA no effect no effect reduction no effect
Phospho-NF-kB no effect no effect reduction no effect
PTGS2/COX2 mRNA no effect no effect drastic increase no effect
PGE2 no effect no effect drastic increase no effect
https://doi.org/10.1371/journal.pone.0174853.t001
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factor productions [32], we also found that it could drastically induce PTGS2/COX2mRNA
levels in THP-1 cells. This was further translated to dramatically increased release of PGE2,
one of the most potent pro-inflammatory prostaglandins [41]. Interestingly, PGE2 promotes
healing in tissue injuries and elevated levels of PGE2 are associated with increased risk of can-
cer [52]. In particular, cyclooxygenase-2 (COX-2) is often expressed in multiple myeloma
(MM) and is a predictor of poor outcome [53] and apoptosis/ treatment resistance. While our
results support the combined use of bortezomib and COX-2 inhibitors for the treatment of
MM [54], it is feasible for future MM research to investigate if the high COX2 MM phenotype
might be potentiated by bortezomib itself.
The current study was undertaken as a result of critical reading of reports on inhibitory
effects of azithromycin, minocycline and bortezomib on MMP-9. Indeed, various overstate-
ments were launched on the basis of clinical studies. First, our findings support the notion that
MMPs are regulated at various levels and these need to be carefully assessed when claiming
inhibitory effects. Second and foremost, the current study clarified that minocycline and azi-
thromycin can specifically act on MMP-9 expression, but, respectively, less or not on its pro-
teolytic activity or activation by MMPs. Another surprising finding of our work was that
bortezomib has limited or no effect on MMP-9 and, besides being highly toxic, drastically
induces the secretion of COX-2 which is translated in high amounts of PGE2.
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S1 Fig. The effect of minocycline, azithromycin, bortezomib and SB-3CT on cell viability
of LPS-stimulated HUVEC cells. Cell viability is expressed as the percentage of cells com-
pared to the control condition (LPS only, no compounds). Individual data points are shown
and the bars represent the mean value. Data were statistically analyzed using a Bonferroni’s
multiple comparison test. , p 0.05; , p 0.01;  p 0.001;  p 0.0001; n = 3.
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S2 Fig. Zymography and qPCR analysis of HUVEC cells challenged with LPS and treated
with minocycline, azithromycin, bortezomib and SB-3CT. (A) Overview image of a repre-
sentative zymography gel. To concentrate the sample, cell culture supernatant was first sub-
jected to gelatin affinity chromatography. Loadings are representative for 25 μl cell culture
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were identical to those in panel A. (C) Fold changes of MMP-2 and TIMP-1 mRNA levels, rel-
ative to the levels from cells treated with LPS only and corrected towards the housekeeping
gene GADPH. Compound concentrations were identical to those in panel A. Individual
data points are shown and the bars represent the mean values. Data were statistically analyzed
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S1 Protocol: HUVEC culture, viability and experimental design. 
HUVECs were cultured in flasks coated with 0.2% gelatin and EGM-2MV medium (Lonza, 
Basel, Switzerland) with 2% FBS. HUVECs (80 000 cells in 2 ml EGM) were seeded in a 
0.2% gelatin coated 12-well plate and allowed to settle for 24 hours. Next, growth medium 
was replaced with serum-free, basal medium (EBM-2) and 50 µl of the test compound was 
added followed by 50 µl of LPS (final concentration of 10 µg/ml). After 24h (37 ºC and 5% 
CO2) the supernatants were collected and the cells were collected in RNA extraction buffer. 
HUVEC cell viability was tested with the use of an alamarBlue® cell viability assay 
(DAL1025 – ThermoFisher Scientific) according to the manufacturer’s instructions. For cell 
culture medium samples, the total protein content was determined and used to normalize 
sample preparation before gelatin zymography. 
  
S1 Figure: The effect of minocycline, azithromycin, bortezomib 
and SB-3CT on cell viability of LPS-stimulated HUVEC cells. 
 
S1 Fig. The effect of minocycline, azithromycin, bortezomib and SB-3CT on cell viability of LPS-stimulated 
HUVEC cells. Cell viability is expressed as the percentage of cells compared to the control condition (LPS only, 
no compounds). Individual data points are shown and the bars represent the mean value. Data were statistically 
analyzed using a Bonferroni's multiple comparison test. *, p ≤ 0.05; **, p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; 
n = 3. 
 
  
S2 Figure: Zymography and qPCR analysis of HUVEC cells 
challenged with LPS and treated with minocycline, azithromycin, 
bortezomib and SB-3CT. 
 
 
S2 Fig. Zymography and qPCR analysis of HUVEC cells challenged with LPS and treated with minocycline, 
azithromycin, bortezomib and SB-3CT. (A) Overview image of a representative zymography gel. To 
concentrate the sample, cell culture supernatant was first subjected to gelatin affinity chromatography. Loadings 
are representative for 25 µl cell culture supernatant. MMP-2 appeared as a constitutively expressed gelatinase and 
no MMP-9 protein was detected. Equal amounts of an internal loading control (±48 kDa MMP-9 mutant lacking 
the O-glycosylated and hemopexin domains) were included to allow correction for sample processing and loading 
errors. hrMMP-9, human recombinant proMMP-9. (B) Relative expression of the mRNAs encoded by the human 
MMP-2, MMP-9 and TIMP-1 genes, as corrected towards that of the housekeeping gene GADPH. While MMP-2 
gene expression levels were high and constitutive, MMP-9 expression was insignificant. Compound concentrations 
were identical to those in panel A. (C) Fold changes of MMP-2 and TIMP-1 mRNA levels, relative to the levels 
from cells treated with LPS only and corrected towards the housekeeping gene GADPH. Compound concentrations 
were identical to those in panel A. Individual data points are shown and the bars represent the mean values. Data 
were statistically analyzed compared to the LPS control using a Bonferroni's multiple comparison test. **, p ≤ 
0.01; **** p ≤ 0.0001; n = 3. 
 
Table S1: Previously described effects of minocycline, azithromycin and bortezomib on MMP-9 
 
Pathology model Conc. tested Effect on MMP-9 Comments References 
   mRNA expression Protein levels activity   
AZITHROMYCIN 
Inflammation In vitro Human gingival cells 0.1 - 10 µg/ml  2  cultured with serum [1]  
Human osteoclasts 20 µg/ml  culture substrate 
dependent 
   [2]  
Human monocytes and 
PBMCs 
33-333 µM  2   [3] 
Co-culture mouse 
fibroblasts and 
macrophages 
30 µM  1  cultured with serum [4] 
Human bronchial epithelial 
cells 
30 µg/ml ,  1   [5, 6]  
In vivo Human allograft 
dysfunction  
  1,2 
Activated MMP-9 
levels2 
MMP-9/NGAL 
levels2 
  [7] 
Sputum COPD patients 250 mg/day 
12 months 
    
 
[8] 
Mouse P. Aeruginosa 
pneumonia, lavage fluids 
0.16 g/kg 
daily 
 1   [4] 
Rat acute conjunctivitis 15 mg/g 
topical ocular 
    [9] 
BORTEZOMIB 
Cancer In vitro Human bladder cells 1 µM  1   [10] 
Human AML cells 25 nM  1   [11] 
myeloma cells and MNC 
from BM of MM patients 
20 - 25 nM  2,3 
Activation 
 10% cell toxicity [12, 13] 
In vivo Orthotopic tumors of 
253JB-V human bladder 
cells 
1 mg/kg  4   [10] 
Inflammation In vivo rat liver I/R injury  0.1 mg/kg Ratio MMP-9/MMP-
2 gene expression 
Activated MMP-9 2 
 
 Activated MMP-2 levels2 
MMP-2 activity 
[14] 
MINOCYCLINE 
Inflammation In vitro Mouse peritoneal 
macrophages 
  2   [15] 
VEGF stimulated HASMCs 13-30 µM  2  MMP-2 mRNA , protein 
2  
TIMP-1 mRNA  
[16] 
Recombinant MMP-9    
 
IC50 = 
180 µM 
IC50 MMP-7 = 125 µM [17] 
TNF-α activated THP-1 
cells 
1 nM     [18] 
RPE cells 25 µM     [19] 
Rat PC12 cells subjected to 
OGD 
200 nM  2   [20] 
Human T-cells 250 µg/ml  3   [21] 
In vivo Mouse/Rat TBI model 
 
90 mg/kg, 
1 mg/kg (i.v.) 
 
 2,3  MMP-2 mRNA and protein 
2,3 
[22-24] 
Mouse DSS-induced colitis 30 mg/kg/day     [25] 
LPS induced 
neuroinflammation 
150 mg/kg  2   [26] 
MCAO in rats 2x 30 
mg/kg/day 
 2   [27] 
Rat nerve graft model 50 mg/kg/day 
(i.p.) 
 3   [28] 
JEV infected mice 2 x 45 
mg/kg/day 
 2   [29] 
ischaemia in rats/ mice 50 mg/kg/day 
45 mg/kg 2x 
per day 
60 mg/kg/12h 
2.5-5 
mg/kg/day 
 2,3,4   [17, 30-35] 
Rabbit atherosclerosis 1.5/kg/day – 3 
mg/kg/day 
 1,4  total 
MMP 
 [18] 
Thromboembolic stroke 
model in mice 
6 mg/kg i.v.  2,3   [36] 
Rats with SAH 1 mg/ kg/24h  3   [37] 
VEGF hyperstimulation 1-100 
mg/kg/day 
(oral) 
 2   [38]  
Mouse EAE model 25 mg/kg/day     [21]  
Rat EAC model 50 mg/kg/day  2   [39]  
Rat EAN model 50 mg/kg/day  4   [40]  
Rat PVD model for small 
vessel-stroke 
45 mg/kg/day  3,4   [41]  
other In vivo Fragile X  syndrome 
patients (plasma) 
  2   [42]  
Fmr1 KO mice 30 mg/kg/day  2,3   [43]  
Rat Alzheimer disease  50 mg/kg/day 
(i.p.) 
 2   [44]  
AML; acute myelogenous leukemia, BCEC; bovine corneal endothelial cells, CoMTb;  conditioned medium from monocytes infected with M. tuberculosis, COPD; chronic 
obstructive pulmonary disease, DSS; dextran sodium sulfate, EAC; experimental autoimmune carditis, EAE; experimental autoimmune encephalomyelitis, EAN; 
Experimental autoimmune neuritis, ELISA; enzyme-linked immunosorbent assay, Fmr; fragile X mental retardation gene, HASMCs; human aortic smooth muscle cells, 
HGF; human gingival fibroblasts, IHC; immunohistochemistry, JEV; Japanese encephalitis virus, LPS; lipopolysaccharide, MCAO; middle cerebral artery occlusion, MM; 
multiple myeloma; MNC; mononuclear cells, OGD; oxygen-glucose deprivation, PBMC; peripheral blood mononuclear cells, PC; pheochromocytoma, PVD; pial vessel 
disruption, RPE; retinal pigment epithelial, SAH; subarachnoid hemorrhage, WB; western blot, 1; protein levels determined by ELISA, 2; protein levels determined by 
gelatin zymography, 3; WB protein levels, 4; IHC protein levels, ; decreased, ; no change, ; increased. 
 
 
1. Kamemoto A, Ara T, Hattori T, Fujinami Y, Imamura Y, Wang PL. Macrolide antibiotics like azithromycin increase lipopolysaccharide-
induced IL-8 production by human gingival fibroblasts. Eur J Med Res. 2009;14(7):309-14. PubMed PMID: 19661014; PubMed Central 
PMCID: PMCPMC3458641. 
2. Gannon SC, Cantley MD, Haynes DR, Hirsch R, Bartold PM. Azithromycin suppresses human osteoclast formation and activity in vitro. 
J Cell Physiol. 2013;228(5):1098-107. doi: 10.1002/jcp.24259. PubMed PMID: 23065774. 
3. Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, et al. A novel macrolide solithromycin exerts superior anti-
inflammatory effect via NF-kappaB inhibition. J Pharmacol Exp Ther. 2013;345(1):76-84. doi: 10.1124/jpet.112.200733. PubMed PMID: 
23359665. 
4. Cory TJ, Birket SE, Murphy BS, Mattingly C, Breslow-Deckman JM, Feola DJ. Azithromycin increases in vitro fibronectin production 
through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa. J Antimicrob Chemother. 
2013;68(4):840-51. doi: 10.1093/jac/dks476. PubMed PMID: 23248239; PubMed Central PMCID: PMCPMC3594493. 
5. Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, et al. Azithromycin treatment alters gene expression in inflammatory, 
lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS One. 2009;4(6):e5806. doi: 
10.1371/journal.pone.0005806. PubMed PMID: 19503797; PubMed Central PMCID: PMCPMC2688381. 
6. Singh S, Kubler A, Singh UK, Singh A, Gardiner H, Prasad R, et al. Antimycobacterial drugs modulate immunopathogenic matrix 
metalloproteinases in a cellular model of pulmonary tuberculosis. Antimicrob Agents Chemother. 2014;58(8):4657-65. doi: 
10.1128/AAC.02141-13. PubMed PMID: 24890593; PubMed Central PMCID: PMCPMC4136059. 
7. Verleden SE, Vandooren J, Vos R, Willems S, Dupont LJ, Verleden GM, et al. Azithromycin decreases MMP-9 expression in the airways 
of lung transplant recipients. Transpl Immunol. 2011;25(2-3):159-62. doi: 10.1016/j.trim.2011.06.006. PubMed PMID: 21740970. 
8. O'Reilly PJ, Jackson PL, Wells JM, Dransfield MT, Scanlon PD, Blalock JE. Sputum PGP is reduced by azithromycin treatment in 
patients with COPD and correlates with exacerbations. BMJ Open. 2013;3(12):e004140. doi: 10.1136/bmjopen-2013-004140. PubMed 
PMID: 24366582; PubMed Central PMCID: PMCPMC3884851. 
9. Fernandez-Robredo P, Recalde S, Moreno-Orduna M, Garcia-Garcia L, Zarranz-Ventura J, Garcia-Layana A. Azithromycin reduces 
inflammation in a rat model of acute conjunctivitis. Mol Vis. 2013;19:153-65. PubMed PMID: 23378729; PubMed Central PMCID: 
PMCPMC3559097. 
10. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, et al. The proteasome inhibitor bortezomib synergizes with 
gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004;3(3):279-90. PubMed PMID: 
15026548. 
11. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O. Primary human acute myelogenous leukemia cells release 
matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol. 2010;84(3):239-51. doi: 
10.1111/j.1600-0609.2009.01382.x. PubMed PMID: 19922462. 
12. Cohen K, Flint N, Shalev S, Erez D, Baharal T, Davis PJ, et al. Thyroid hormone regulates adhesion, migration and matrix 
metalloproteinase 9 activity via alphavbeta3 integrin in myeloma cells. Oncotarget. 2014;5(15):6312-22. doi: 10.18632/oncotarget.2205. 
PubMed PMID: 25071016; PubMed Central PMCID: PMCPMC4171632. 
13. Lee JH, Chiang SY, Nam D, Chung WS, Lee J, Na YS, et al. Capillarisin inhibits constitutive and inducible STAT3 activation through 
induction of SHP-1 and SHP-2 tyrosine phosphatases. Cancer Lett. 2014;345(1):140-8. doi: 10.1016/j.canlet.2013.12.008. PubMed 
PMID: 24333736. 
14. Tiriveedhi V, Upadhya GA, Busch RA, Gunter KL, Dines JN, Knolhoff BL, et al. Protective role of bortezomib in steatotic liver 
ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression. Transpl Immunol. 2014;30(2-3):93-8. doi: 
10.1016/j.trim.2013.12.003. PubMed PMID: 24380732. 
15. Dutta K, Mishra MK, Nazmi A, Kumawat KL, Basu A. Minocycline differentially modulates macrophage mediated peripheral immune 
response following Japanese encephalitis virus infection. Immunobiology. 2010;215(11):884-93. doi: 10.1016/j.imbio.2009.12.003. 
PubMed PMID: 20153075. 
16. Yao JS, Shen F, Young WL, Yang GY. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle 
cell migration. Neurochem Int. 2007;50(3):524-30. doi: 10.1016/j.neuint.2006.10.008. PubMed PMID: 17145119; PubMed Central 
PMCID: PMCPMC1876824. 
17. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, et al. Cardiac uptake of minocycline and 
mechanisms for in vivo cardioprotection. J Am Coll Cardiol. 2008;52(13):1086-94. doi: 10.1016/j.jacc.2008.06.028. PubMed PMID: 
18848143; PubMed Central PMCID: PMCPMC2572824. 
18. Ohshima S, Fujimoto S, Petrov A, Nakagami H, Haider N, Zhou J, et al. Effect of an antimicrobial agent on atherosclerotic plaques: 
assessment of metalloproteinase activity by molecular imaging. J Am Coll Cardiol. 2010;55(12):1240-9. doi: 10.1016/j.jacc.2009.11.056. 
PubMed PMID: 20298932. 
19. Hollborn M, Wiedemann P, Bringmann A, Kohen L. Chemotactic and cytotoxic effects of minocycline on human retinal pigment 
epithelial cells. Invest Ophthalmol Vis Sci. 2010;51(5):2721-9. doi: 10.1167/iovs.09-4661. PubMed PMID: 20019360. 
20. Chen X, Chen S, Jiang Y, Zhu C, Wu A, Ma X, et al. Minocycline reduces oxygen-glucose deprivation-induced PC12 cell cytotoxicity 
via matrix metalloproteinase-9, integrin beta1 and phosphorylated Akt modulation. Neurol Sci. 2013;34(8):1391-6. doi: 10.1007/s10072-
012-1246-z. PubMed PMID: 23224583. 
21. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a 
potential therapy for multiple sclerosis. Brain. 2002;125(Pt 6):1297-308. PubMed PMID: 12023318. 
22. Ding JY, Kreipke CW, Schafer P, Schafer S, Speirs SL, Rafols JA. Synapse loss regulated by matrix metalloproteinases in traumatic brain 
injury is associated with hypoxia inducible factor-1alpha expression. Brain Res. 2009;1268:125-34. doi: 10.1016/j.brainres.2009.02.060. 
PubMed PMID: 19285046; PubMed Central PMCID: PMCPMC2668731. 
23. Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, et al. The role of hypoxia-inducible factor-1alpha, aquaporin-4, and 
matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg. 2011;114(1):92-
101. doi: 10.3171/2010.6.JNS10207. PubMed PMID: 20617879. 
24. Homsi S, Federico F, Croci N, Palmier B, Plotkine M, Marchand-Leroux C, et al. Minocycline effects on cerebral edema: relations with 
inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res. 2009;1291:122-32. doi: 
10.1016/j.brainres.2009.07.031. PubMed PMID: 19631631. 
25. Garrido-Mesa N, Utrilla P, Comalada M, Zorrilla P, Garrido-Mesa J, Zarzuelo A, et al. The association of minocycline and the probiotic 
Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem Pharmacol. 
2011;82(12):1891-900. doi: 10.1016/j.bcp.2011.09.004. PubMed PMID: 21930116. 
26. Rosenberg GA, Estrada EY, Mobashery S. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-
brain barrier opening in rodents: Differences in response based on strains and solvents. Brain Res. 2007;1133(1):186-92. doi: 
10.1016/j.brainres.2006.11.041. PubMed PMID: 17184743; PubMed Central PMCID: PMCPMC1861831. 
27. Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, et al. Minocycline and hypothermia for reperfusion injury after focal 
cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res. 2008;1188:198-
206. doi: 10.1016/j.brainres.2007.10.052. PubMed PMID: 18031717. 
28. Keilhoff G, Schild L, Fansa H. Minocycline protects Schwann cells from ischemia-like injury and promotes axonal outgrowth in 
bioartificial nerve grafts lacking Wallerian degeneration. Exp Neurol. 2008;212(1):189-200. doi: 10.1016/j.expneurol.2008.03.028. 
PubMed PMID: 18501894. 
29. Mishra MK, Dutta K, Saheb SK, Basu A. Understanding the molecular mechanism of blood-brain barrier damage in an experimental 
model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent. Neurochem Int. 2009;55(8):717-23. 
doi: 10.1016/j.neuint.2009.07.006. PubMed PMID: 19628016. 
30. Elgebaly MM, Prakash R, Li W, Ogbi S, Johnson MH, Mezzetti EM, et al. Vascular protection in diabetic stroke: role of matrix 
metalloprotease-dependent vascular remodeling. J Cereb Blood Flow Metab. 2010;30(12):1928-38. doi: 10.1038/jcbfm.2010.120. 
PubMed PMID: 20664613; PubMed Central PMCID: PMCPMC3002883. 
31. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, et al. Minocycline protects against permanent cerebral 
ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab. 2005;25(4):460-7. doi: 
10.1038/sj.jcbfm.9600040. PubMed PMID: 15674236. 
32. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix 
metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006;7:56. doi: 10.1186/1471-2202-7-56. PubMed PMID: 
16846501; PubMed Central PMCID: PMCPMC1543649. 
33. Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH. Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann 
Neurol. 2006;59(6):929-38. doi: 10.1002/ana.20850. PubMed PMID: 16673393. 
34. Mathalone N, Lahat N, Rahat MA, Bahar-Shany K, Oron Y, Geyer O. The involvement of matrix metalloproteinases 2 and 9 in rat retinal 
ischemia. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):725-32. doi: 10.1007/s00417-006-0362-y. PubMed PMID: 17024442. 
35. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of 
ischemic renal injury. Am J Physiol Renal Physiol. 2005;288(1):F91-7. doi: 10.1152/ajprenal.00051.2004. PubMed PMID: 15353401. 
36. Hoda MN, Li W, Ahmad A, Ogbi S, Zemskova MA, Johnson MH, et al. Sex-independent neuroprotection with minocycline after 
experimental thromboembolic stroke. Exp Transl Stroke Med. 2011;3(1):16. doi: 10.1186/2040-7378-3-16. PubMed PMID: 22177314; 
PubMed Central PMCID: PMCPMC3287111. 
37. Wang Z, Meng CJ, Shen XM, Shu Z, Ma C, Zhu GQ, et al. Potential contribution of hypoxia-inducible factor-1alpha, aquaporin-4, and 
matrix metalloproteinase-9 to blood-brain barrier disruption and brain edema after experimental subarachnoid hemorrhage. J Mol 
Neurosci. 2012;48(1):273-80. doi: 10.1007/s12031-012-9769-6. PubMed PMID: 22528459. 
38. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, et al. Dose-response effect of tetracyclines on cerebral matrix 
metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006;26(9):1157-64. doi: 
10.1038/sj.jcbfm.9600268. PubMed PMID: 16395286. 
39. Matsumoto Y, Park IK, Kohyama K. Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression 
of C protein-induced myocarditis and subsequent dilated cardiomyopathy. J Immunol. 2009;183(7):4773-81. doi: 
10.4049/jimmunol.0900871. PubMed PMID: 19734212. 
40. Zhang ZY, Zhang Z, Fauser U, Schluesener HJ. Improved outcome of EAN, an animal model of GBS, through amelioration of peripheral 
and central inflammation by minocycline. J Cell Mol Med. 2009;13(2):341-51. doi: 10.1111/j.1582-4934.2008.00333.x. PubMed PMID: 
18400050; PubMed Central PMCID: PMCPMC3823360. 
41. Cayabyab FS, Gowribai K, Walz W. Involvement of matrix metalloproteinases-2 and -9 in the formation of a lacuna-like cerebral cavity. 
J Neurosci Res. 2013;91(7):920-33. doi: 10.1002/jnr.23223. PubMed PMID: 23606560. 
42. Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, et al. High MMP-9 activity levels in fragile X syndrome are 
lowered by minocycline. Am J Med Genet A. 2013;161A(8):1897-903. doi: 10.1002/ajmg.a.36023. PubMed PMID: 23824974. 
43. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. Minocycline promotes dendritic spine maturation and improves 
behavioural performance in the fragile X mouse model. J Med Genet. 2009;46(2):94-102. doi: 10.1136/jmg.2008.061796. PubMed 
PMID: 18835858. 
44. Bruno MA, Leon WC, Fragoso G, Mushynski WE, Almazan G, Cuello AC. Amyloid beta-induced nerve growth factor dysmetabolism in 
Alzheimer disease. J Neuropathol Exp Neurol. 2009;68(8):857-69. doi: 10.1097/NEN.0b013e3181aed9e6. PubMed PMID: 19606067. 
 
 
 
